Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip R Greipp

Showing results (91-100 of 113) with videos related to

Pageof 12
Sort By:
British Journal of Haematology|April 14, 2006
Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemiaIrene M Ghobrial, Rafael Fonseca, Morie A Gertz, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myelomaPrashant Kapoor, Shaji K Kumar, Angela Dispenzieri, et al.
Blood|January 17, 2004
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myelomaMelissa Alsina, Rafael Fonseca, Edward F Wilson, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
Blood|May 28, 2005
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUSWee Joo Chng, Scott A Van Wier, Gregory J Ahmann, et al.
Blood|February 13, 2008
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupHeinz Ludwig, Brian G M Durie, Vanessa Bolejack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
International staging system for multiple myelomaPhilip R Greipp, Jesus San Miguel, Brian G M Durie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myelomaMartha Q Lacy, Suzanne R Hayman, Morie A Gertz, et al.
Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
British Journal of Haematology|April 14, 2006
Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemiaIrene M Ghobrial, Rafael Fonseca, Morie A Gertz, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myelomaPrashant Kapoor, Shaji K Kumar, Angela Dispenzieri, et al.
Blood|January 17, 2004
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myelomaMelissa Alsina, Rafael Fonseca, Edward F Wilson, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
Blood|May 28, 2005
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUSWee Joo Chng, Scott A Van Wier, Gregory J Ahmann, et al.
Blood|February 13, 2008
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupHeinz Ludwig, Brian G M Durie, Vanessa Bolejack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
International staging system for multiple myelomaPhilip R Greipp, Jesus San Miguel, Brian G M Durie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myelomaMartha Q Lacy, Suzanne R Hayman, Morie A Gertz, et al.
Pageof 12